US2004018960A1PendingUtilityA1
Water soluble paclitaxel derivatives
Est. expiryMar 12, 2016(expired)· nominal 20-yr term from priority
A61K 31/4375A61L 2300/416A61K 47/60A61K 47/645A61K 31/337A61L 31/10A61L 2300/606A61K 51/0497A61P 35/02A61K 41/0038C08G 73/1092A61K 38/13A61K 51/065A61K 47/59A61K 2123/00A61P 35/00A61K 47/547A61L 31/16A61K 2121/00A61P 35/04
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method for treating cancer in a subject, comprising administering to a subject having cancer a water soluble conjugate comprising camptothecin in combination with a platinum drug.
2 . The method of claim 1 , wherein said water soluble conjugate comprises, wherein said water soluble conjugate comprises a water soluble polymer conjugated to said camptothecin.
3 . The method of claim 2 , wherein said water soluble polymer is polyglutamate.
4 . The method of claim 3 , wherein said polyglutamate is poly(1-glutamic acid).
5 . The method of claim 4 , wherein said polyglutamic acid has a molecular weight of about 5000 to about 100,000 daltons.
6 . The method of claim 5 , wherein polyglutamic acid has a molecular weight of about 20,000 to about 80,000 daltons.
7 . The method of claim 6 , wherein polyglutamic acid has a molecular weight of about 25,000 to about 50,000 daltons.
8 . The method of claim 7 , wherein said composition comprises from about 2% to about 35% by weight of camptothecin.
9 . The method of claim 8 , wherein said composition comprises about 32% by weight of camptothecin.
10 . The method of claim 9 , wherein said cancer is breast cancer, ovarian cancer, malignant melanoma, lung cancer, gastric cancer, prostate cancer, colon cancer, head and neck cancer, leukemia or Kaposi's sarcoma.
11 . The method of claim 10 , wherein said cancer is ovarian cancer.
12 . The method of claim 10 , wherein said cancer is lung cancer.
13 . The method of claim 10 , wherein said cancer is colon cancer.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.